Safety of treatment with biologics for psoriasis in daily practice: 5-year data

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 283-291

  Van Lumig P P M ^a   Driessen, R J B ^a   Berends, M A M ^a   Boezeman, J B M ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ABSCESS; ADULT; ANGINA PECTORIS; ANUS FISTULA; ARTHRITIS; ARTHROPATHY; ARTICLE; ASTHMA; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; COLON CANCER; CONGESTIVE CARDIOMYOPATHY; CYSTOCELE; DRUG SAFETY; ENDOMETRIUM POLYP; ENTHESOPATHY; ERYSIPELAS; ESOPHAGUS CARCINOMA; ESOPHAGUS VARICES BLEEDING; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INGUINAL HERNIA; INJECTION SITE REACTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NEPHROLITHIASIS; PATENT DUCTUS ARTERIOSUS; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PUVA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SPONTANEOUS ABORTION; SQUAMOUS CELL CARCINOMA; STOMACH DISEASE; WEIGHT REDUCTION;

AGED; BIOLOGICAL AGENTS; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; TREATMENT OUTCOME;

EID: 84857373425     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04044.x     Document Type: Article

References (19)

1. Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-1017.
2. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
3. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
4. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666-R676.
5. Berends MA, Driessen RJ, Langewouters AM, et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 2007; 18: 76-83. (Pubitemid 46801841)
6. Driessen RJ, Berends MA, Boezeman JB, et al. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol 2008; 158: 1098-1106. (Pubitemid 351521467)
7. Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
8. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
9. World Health Organization. International statistical classification of diseases and related health problems 10th revision version for 2007.
10. van de Lisdonk EH, van den Bosch WJHM, Lagro-Janssen ALM, et al. Ziekten in de Huisartspraktijk. Vijfde Druk. Elsevier gezondheidszorg, Maarssen, 2008.
11. van Weel C. The Continuous Morbidity Registration Nijmegen: background and history of a Dutch general practice database. Eur J Gen Pract 2008; 14 (Suppl. 1): 5-12.
12. European Medicines Agency. ICH topic E 2 A clinical safety data management: definitions and standards for expedited reporting. Approved: November 1994.
13. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-1426. (Pubitemid 41623851)
14. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-1869.
15. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895. (Pubitemid 47502734)
16. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-1537. (Pubitemid 34032784)
17. Ji J, Shu X, Sundquist K, et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009; 100: 1499-1502.
18. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 697-705.
19. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-641.